Cerebrolysin® is safe and well tolerated! The experience with Cerebrolysin® during many years of clinical application, the information from post-marketing surveillance studies, the safety data from double-blind, placebo-controlled clinical trials and EVER’s pharmacovigilance database demonstrate the excellent clinical safety profile of Cerebrolysin®.

According to EMA classification (European Medicines Agency), Cerebrolysin® is in the SAFE category. In general, reported adverse drug reactions are transient and mild in intensity.